| scholarly article | Q13442814 |
| P2093 | author name string | L H Calabrese | |
| C Calabrese | |||
| E Kirchner | |||
| K Kontzias | |||
| V Velcheti | |||
| P2860 | cites work | Safety, activity, and immune correlates of anti-PD-1 antibody in cancer | Q24633070 |
| Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer | Q27860857 | ||
| Improved Survival with Ipilimumab in Patients with Metastatic Melanoma | Q27861062 | ||
| Immune checkpoint blockade: a common denominator approach to cancer therapy | Q28083981 | ||
| Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination | Q30251438 | ||
| Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center | Q37380454 | ||
| Fulminant Myocarditis with Combination Immune Checkpoint Blockade | Q37595462 | ||
| Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders. | Q38657957 | ||
| Immune-related adverse events with immune checkpoint blockade: a comprehensive review | Q38696141 | ||
| Cancer immunotherapy in patients with preexisting autoimmune disorders | Q38978399 | ||
| Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. | Q50626424 | ||
| P433 | issue | 1 | |
| P304 | page(s) | e000412 | |
| P577 | publication date | 2017-03-20 | |
| P1433 | published in | RMD open | Q27726913 |
| P1476 | title | Rheumatic immune-related adverse events of checkpoint therapy for cancer: case series of a new nosological entity | |
| P478 | volume | 3 |
| Q90157687 | A case report of immune-mediated arthritis in a patient with cutaneous melanoma receiving checkpoint inhibition therapy |
| Q92052685 | Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance |
| Q92763346 | Association between immune-related adverse events and prognosis in patients with metastatic renal cell carcinoma treated with nivolumab |
| Q90215056 | Association of HLA-DRB1 shared epitope alleles and immune checkpoint inhibitor-induced inflammatory arthritis |
| Q58768975 | Characteristics and treatment of new-onset arthritis after checkpoint inhibitor therapy |
| Q51764698 | Checks and Balances in Autoimmune Vasculitis. |
| Q91801539 | Clinical characteristics of rheumatic syndromes associated with checkpoint inhibitors therapy |
| Q56892765 | Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen |
| Q92404929 | Decreased Expression of Negative Immune Checkpoint VISTA by CD4+ T Cells Facilitates T Helper 1, T Helper 17, and T Follicular Helper Lineage Differentiation in GCA |
| Q90178658 | Do current approaches to assessing therapy related adverse events align with the needs of long-term cancer patients and survivors? |
| Q91801554 | Frequency and distribution of various rheumatic disorders associated with checkpoint inhibitor therapy |
| Q92684962 | How I treat cancer: treatment of rheumatological side effects of immunotherapy |
| Q90196414 | Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation |
| Q55426703 | Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook. |
| Q91786172 | Immune-Related Adverse Events: A Case-Based Approach |
| Q90587259 | Immune-related adverse events in cancer patients treated with immune checkpoint inhibitors: A single-center experience |
| Q57280959 | Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: a seminal case series |
| Q57491552 | Inflammatory Arthritis Induced by Pembrolizumab in a Patient With Head and Neck Squamous Cell Carcinoma |
| Q92867594 | Management of immune checkpoint inhibitor-related adverse events: A review of case reports |
| Q91801513 | Management of rheumatic complications of ICI therapy: a rheumatology viewpoint |
| Q91801518 | Management of rheumatic complications of immune checkpoint inhibitor therapy - an oncological perspective |
| Q91801526 | Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors |
| Q50000744 | Metastatic joint involvement or inflammatory arthritis? A conundrum with immune checkpoint inhibitor-related adverse events. |
| Q56893186 | Musculoskeletal and Rheumatic Diseases Induced by Immune Checkpoint Inhibitors: A Review of the Literature |
| Q92320729 | Pembrolizumab-Induced Seronegative Arthritis and Fasciitis in a Patient with Lung Adenocarcinoma |
| Q97538211 | Polymyalgia rheumatica in a melanoma patient 11 months after completion of immunotherapy with nivolumab |
| Q64983127 | Polymyalgia rheumatica-like syndrome from checkpoint inhibitor therapy: case series and systematic review of the literature. |
| Q64056235 | Recurrent pseudogout after therapy with immune checkpoint inhibitors: a case report with immunoprofiling of synovial fluid at each flare |
| Q90242060 | Rheumatic complications in cancer patients treated with immune checkpoint inhibitors |
| Q57143926 | Rheumatic immune-related adverse events from cancer immunotherapy |
| Q47164715 | Safety of checkpoint inhibitors for cancer treatment: strategies for patient monitoring and management of immune-mediated adverse events |
| Q93161413 | Sicca Syndrome Associated with Immune Checkpoint Inhibitor Therapy |
| Q89647019 | Sicca Syndrome Induced by Immune Checkpoint Inhibitor Therapy: Optimal Management Still Pending |
| Q89580968 | The relationships between cancer and autoimmune rheumatic diseases |
| Q90301628 | Treatment of immune checkpoint inhibitor-induced inflammatory arthritis |
Search more.